Akèy › Limfòm folikilè › Washington
Etid klinik pou Limfòm folikilè nan Washington
19 etid pou Limfòm folikilè ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Swedish Cancer Institute (SCI), Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Fred Hutchinson Cancer Research Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT05765812A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Tacoma
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou Sep 21, 2026 · NCT06549595Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Northwest Medical Specialties, Tacoma
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Sep 11, 2026 · NCT06784752SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Fred Hutch Cancer Center, Seattle
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06442475A Study of ARC-02 in B-cell NHL
- Summit Cancer Centers - North Spokane, Spokane
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07121946Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06948786Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 2Volontè an sante akeyi
6 Months · Tout sèks · Mizajou May 29, 2026 · NCT04195633A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Local Institution - 0143, Vancouver
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06911502Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- University of Washington-Seattle Cancer Care Alliance, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 30, 2026 · NCT04669171SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Swedish Cancer Institute, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
- University of Washington Medical Center, Seattle
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2021 · NCT02537769Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.